Multiplier AI Blog
Know How Data, AI, & Digital Marketing Can Help Pharma & Life Sciences
What Is a GenAI Doctor Data Platform and Why Pharma Commercial Teams Are Adopting It
Pharma companies no longer need only doctor databases. They need doctor intelligence. A GenAI doctor data platform helps commercial teams move from static physician records to AI-powered insights that explain how HCPs engage, decide, and respond across channels.
Doctor Data Validation: The Critical Step Most Pharma Commercial Teams Skip
Most pharma commercial teams invest heavily in CRM platforms, targeting systems, and AI-driven engagement tools. But if the underlying physician data is inaccurate, every downstream decision becomes unreliable.
Prescriber Segmentation in 2026: Moving Beyond Specialty and Prescription Volume
Most pharma teams still segment prescribers using specialty, location, and prescription volume. But in 2026, that is no longer enough. The real opportunity is understanding how physicians think, engage, adopt therapies, and respond to scientific communication.
How to Build a 360 Degree HCP Profile Using AI and Real Time Data
Pharma teams often have doctor data, but not doctor intelligence. A 360 degree HCP profile solves this gap by unifying CRM, prescribing, digital, behavioral, and engagement data into one real-time physician view.
Duplicate Doctor Records in Pharma CRM: The Hidden Costs (and How to Fix Them in 2026)
Duplicate doctor records are physician profiles that appear multiple times in a pharma CRM under slightly different names, affiliations, or formatting.
Why Static HCP Lists Are Failing Pharma in 2026 (and What Replaces Them)
For decades, pharma commercial teams have run on static HCP lists — predefined groups of physicians refreshed once or twice a year and handed to sales reps as visit plans.
Why Pharma Commercial Teams Need AI-Driven HCP Segmentation
Most pharma commercial teams believe better segmentation will improve engagement. The truth is sharper: even the most advanced AI-driven HCP segmentation fails when the data and consent foundations underneath it are broken.
Why Your Doctor Database in Pharma Is Costing You More Than You Think
Most pharma companies think their biggest problem is acquiring more doctor data. The bigger problem is the doctor database they already have.
Why Pharma CRMs Fail at Consent Tracking ?
Most pharma companies believe their CRM systems are ready for DPDP compliance. After all, consent fields exist, opt out flags are present, and suppression lists are maintained. On paper, this looks sufficient.
Consent Enforcement at the Point of Engagement: What Pharma Must Do?
Most pharma companies believe they are compliant because consent exists somewhere in their CRM or databases. Under the Digital Personal Data Protection Act 2023, that belief is not enough.
Why Opt In Is Not Enough Under DPDP Act in Pharma?
Opt-in built pharma's marketing engine. The DPDP Act 2023 just rewrote the rules. Here's why opt-in alone no longer counts as consent.
Why Pharma Companies Qualify as Significant Data Fiduciaries Under DPDP?
The Digital Personal Data Protection Act 2023 introduces an important concept that many pharma companies have not yet fully internalised: the idea of a Significant Data Fiduciary.